Bristol Myers Squibb has entered a strategic agreement with Anthropic to deploy Claude across research, clinical development, manufacturing, commercial, and corporate functions, giving more than 30,000 employees access to advanced reasoning and agentic AI capabilities. The deal, announced May 20, positions Claude as BMS’s “shared intelligence platform” across its global operations, according to the company’s press release.
Three Priority Areas
BMS is focusing the deployment on three priority areas, according to PharmExec.
In engineering, teams will use Claude Code to accelerate internal software and AI development, standardizing how capabilities are built across the enterprise. In core drug development workflows, Claude will serve as an agentic layer across clinical trial documentation, manufacturing quality processes, and commercial operations. Specific applications include synthesizing decades of proprietary scientific data, drafting clinical study reports from underlying datasets, supporting regulatory submissions, and identifying root causes of manufacturing deviations in real time.
The third priority connects Claude to institutional knowledge distributed across BMS’s systems, with full enterprise governance and audit controls.
“Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos, and this collaboration is how we reach it,” said Greg Meyers, EVP and chief digital and technology officer at BMS, according to PharmExec. “Anthropic’s Claude gives us the agentic capabilities, pace of innovation, and security necessary to connect our systems and put that collective knowledge in the hands of every BMS employee to accelerate innovation for patients.”
Pharma as Regulated AI Proving Ground
The agreement builds on over three years of AI investment at BMS and reflects what PharmExec described as “a growing industry trend for companies using AI, aiming to move beyond productivity tools toward deeply integrated systems capable of operating autonomously across core scientific and business functions.”
Pharma is emerging as a key vertical for Anthropic’s enterprise strategy. The industry’s regulatory requirements, from FDA submission standards to manufacturing quality documentation, create a natural fit for Anthropic’s safety-first positioning. BMS’s deployment requires auditability and governance controls that consumer-oriented AI products typically do not provide, and Claude Enterprise’s architecture is built to deliver those guardrails.
Competitive Positioning Against OpenAI
The deal also signals market segmentation in the enterprise AI race. While OpenAI has dominated consumer adoption and general productivity through Copilot integrations and ChatGPT, Anthropic is carving out regulated verticals where safety guarantees and audit trails carry more weight than raw capability. BMS’s decision to deploy Claude as a company-wide foundation model, rather than supplementing an existing OpenAI or in-house stack, represents a deliberate platform choice.
Anthropic’s enterprise momentum comes as the company prepares to close a $30 billion funding round at a valuation exceeding $900 billion. The company’s annualized revenue run rate surpassed $30 billion, up from $9 billion at the end of 2025, according to CNBC. Deals like BMS explain the trajectory: enterprise customers deploying Claude not as a chat tool but as operational infrastructure across tens of thousands of seats.